Atara Biotherapeutics, Inc. is a pharmaceutical company based in the United States of America. With a Risk Rating Score of 26.2, it is considered to be of Medium Risk. Atara Biotherapeutics focuses on developing innovative therapies for patients with serious diseases such as solid tumors, hematologic cancers, and autoimmune diseases. The company's portfolio includes product candidates like Tab-cel, ATA188, and ATA3219 (CAR T Platform). Operating in the healthcare sector, Atara Biotherapeutics is committed to ESG principles of sustainability, environmental responsibility, and good governance.